Small MoleculesAug 14, 2025
Selecting the Right Solid Form-Faster, Smarter, Better
At Porton J-Star, we employ an integrated approach to identify and select the most suitable solid form for development (Figure 2). We conduct effective screen and rigorous assessments for polymorphs, salts, cocrystals, as well as amorphous solid dispersions, by applying our comprehensive expertise and experience.
Small MoleculesJul 21, 2025
Fast and Efficient：Significant Cost Reduction of a Starting Material
3 parallel chemical reactions, controlled crystallization process. Successful preparation, purification and characterization of all relevant impurities. High quality product. Successful development of relevant analytical methods. Successful cross-team and cross-site collaboration.
Small MoleculesJun 27, 2025
Multiple Approaches to Address the Challenges of Oral Absorption of PROTAC Drugs
As a global CDMO serving global innovative pharmaceutical companies and research institutions, Porton has an extensive experience in research and manufacturing services, especially in the field of PROTAC drug development. Porton is committed to the development and production of PROTAC oral formulations and provides customers with comprehensive, reliable, fast, and compliant one-stop services, to meet customers' supply chain needs and facilitating the commercial success of their products from research and development to order fulfillment.
Small MoleculesApr 27, 2025
Comprehensive Analytical R&D and QC Expertise in Pharmaceutical Development
This white paper details our extensive capabilities in Analytical Research and Development (R&D) and Quality Control (QC) for pharmaceutical drug development. It highlights our expertise in method development, structure elucidation, and method troubling. Our goal is to ensure the highest standards of quality and efficiency in drug development and manufacturing.
Small MoleculesMar 13, 2025
Facilitating PROTAC Drugs Development with Innovative Processes
The PROTAC technology, through an innovative mechanism of "degradation rather than inhibition," provides a new pathway for targeting traditionally undruggable proteins and addressing resistance issues.
Small MoleculesJan 06, 2025
Continuous Improvement of Project Life Cycle Management, Benefiting Customers by Reducing Total Cost
Continuous Improvement of Project Life Cycle Management, Benefiting Customers by Reducing Total Cost
Small MoleculesNov 25, 2024
Co-processing: Co-Precipitation Technology (CPT) for the Enhancement of Flowability and Bulk Density
Formulating compressed tablets is one of the most widely used oral solid form dosages. However, a vital first step is choosing a suitable manufacturing approach and the right excipients to support the desired therapeutic effect.
Small MoleculesNov 09, 2024
ENT-03 GRC Poster
ENT-03 was predicted to be the mammalian equivalent of trodusquemine, based on knowledge of the bile acids produced in mammals, such as 7-HOCA. The individual C-25 isomers of ENT-03 were prepared and both detected in mouse brain. Trodusquemine and ENT-03 have both demonstrated dramatic effects in obesity and insulin resistance. (25S)-ENT-03 was selected for development for the treatment of diabetes and obesity.
